Scout | Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Optional)

This opportunity is no longer accepting applications.

grant

Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Optional)

This grant opportunity aims to speed up the development of reliable biomarkers for Alzheimer's disease and related dementias. These biomarkers are intended to be used in discovering and developing medical treatments, conducting clinical trials, and improving clinical practices. The grant will support the validation of these biomarkers to a high standard, similar to the FDA's Biomarker Qualific…

Source

Agency: National Institutes of Health

Sub-agency: National Institute on Aging

Program: SBIR

Dates

Opportunity Released: August 16, 2023

Open for Submission: August 16, 2023

Submission Deadline: March 5, 2026

Application Window Closes: March 5, 2026

Keywords

Alzheimer's disease

AD-related dementias

biomarkers

therapy development

medical product discovery

clinical trials

clinical practice

analytical validation

biomarker qualification

FDA regulatory pathways.

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers